^
Association details:
| Biomarker: | HR negative |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience
Published date:
11/30/2021
Excerpt:
This research included 111 patients with metastatic HER2 positive breast cancer who received lapatinib with capecitabine...Patients with negative prognostic factors such as hormone receptor negativity...had no distinctly worse OS, regardless of receiving lapatinib after prior exposure to trastuzumab, pertuzumab and/or T-DM1 or without prior exposure. Lapatinib with capecitabine is an effective therapeutic option, especially in patients with negative prognostic factors...
Secondary therapy:
capecitabine
DOI:
10.1080/1120009X.2021.2009722
